Discovery Companies
|
Company
|
Market
Cap1 |
Revenues
TTM2 |
Net Income
TTM2
|
|
Celera Genomics (CRA)
|
616.0 |
105.1 |
(114.1)
|
|
CuraGen Corp. (CRGN)
|
203.6 |
18.3 |
(90.4)
|
|
deCODE genetics Inc. (DCGN)
|
99.0 |
38.2 |
(130.0)
|
|
Deltagen Inc. (DGEN)
|
13.9 |
15.4 |
(101.0)
|
|
DNAPrint Genomics (DNAP.OB)
|
9.0 |
0.1 |
(3.5)
|
|
Exelixis Inc. (EXEL)
|
401.7 |
44.3 |
(85.0)
|
|
Genome Therapeutics Corp. (GENE)
|
33.5 |
23.0 |
(34.0)
|
|
Human Genome Sciences (HGSI)
|
1096.9 |
3.6 |
(219.7)
|
|
Hyseq Inc. (HYSQ)
|
18.4 |
33.9 |
(29.9)
|
|
Incyte Genomics Inc. (INCY)
|
203.7 |
101.6 |
(136.8)
|
|
Interleukin Genetics Inc. (ILGN)
|
12.9 |
0.3 |
(5.3)
|
|
Lexicon Genetics Inc. (LEXG)
|
222.7 |
35.2 |
(59.7)
|
|
Millennium Pharmaceuticals (MLNM)
|
2431.9 |
353.1 |
(590.2)
|
|
Myriad Genetics Inc. (MYGN)
|
279.7 |
59.7 |
(22.5)
|
|
Oxford GlycoSciences (ADR) (OGSI)
|
166.2 |
16.1 |
(58.2)
|
|
Rigel Pharmaceuticals Inc. (RIGL)
|
32.4 |
15.8 |
(37.0)
|
|
Sequenom Inc. (SQNM)
|
74.9 |
30.9 |
(205.2)
|
|
Vertex Pharmaceuticals (VRTX)
|
840.4 |
161.1 |
(108.7)
|
Q1 2003 Index = 6,757
Tools Companies
|
Company
|
Market
Cap1 |
Revenues
TTM2 |
Net Income
TTM2
|
|
Aclara Biosciences (ACLA)
|
72.6 |
2.6 |
(37.3)
|
|
Affymetrix Inc. (AFFX)
|
1560.4 |
289.9 |
(1.7)
|
|
Applied Biosystems Group (ABI)
|
3329.0 |
1666.6 |
150.6
|
|
Ciphergen Biosystems (CIPH)
|
155.3 |
39.3 |
(29.1)
|
|
Compugen Ltd. (CGEN)
|
48.6 |
11.1 |
(12.2)
|
|
Epoch Biosciences Inc. (EBIO)
|
39.8 |
11.3 |
(3.2)
|
|
Harvard Bioscience Inc. (HBIO)
|
110.7 |
57.4 |
0.7
|
|
Illumina Inc. (ILMN)
|
76.7 |
10.1 |
(40.3)
|
|
Invitrogen Corp. (IVGN)
|
1528.5 |
648.6 |
47.7
|
|
LION bioscience AG (ADR) (LEON)
|
61.7 |
36.6 |
(165.3)
|
|
Luminex Corp. (LMNX)
|
135.3 |
13.1 |
(24.3)
|
|
Qiagen N.V. (QGENF)
|
858.5 |
298.3 |
23.2
|
|
Third Wave Technologies (TWTI)
|
130.0 |
32.3 |
(40.8)
|
|
Transgenomic Inc. (TBIO)
|
38.8 |
37.5 |
(15.4)
|
|
Varian Inc. (VARI)
|
996.8 |
791.4 |
51.8
|
Q1 2003 Index = 9,143
-
- Market cap is number of shares outstanding x share price as of April 2, 2003 (in $ millions).
- TTM is trailing 12 months ending Dec. 31, 2002, for all companies except Deltagen and DNAPrint Genomics, for which TTM ends Sept. 30, 2002, and Oxford GlycoSciences, for which TTM ends June 30, 2002 (all financials in $ millions).
- TTM is trailing 12 months ending Dec. 31, 2002, for all companies (all financials in $ millions).
RCW Mirus Inc. does not assume any liability for errors or omissions.
Back to Discovering the Joy of Cannibalism